Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-04-16

Development of in-vitro neural systems for the identification of agents with toxicological and pharmacological potential

Obiettivo

To utilise the in vitro systems developed in BAP to clarify the mechanisms of action of compounds particularly analogues of endogenous neuroactive aminoacids with pharmacological and toxicological properties involved with brain cell synaptic functioning, proliferation and differentiation, in order to evaluate their potential as anticonvulsants; neuroprotective agents in excitotoxin-mediated neurodegenerative disease e.g. ischaemia and epilepsy; anti-gliosis agents and anticancer drugs; and their effects as causative agents in the processes of cytotoxicity, epilepogenicity and other convulsive states.
These investigations show that neural cell culture systems have important uses in identifying and screening compounds for toxic and beneficial properties. These methods are strengthened by emphasis on the elucidation of mechanisms of action. Competitive polymeracse chain reaction (PCR) technology has improved the sensitivity of the assay for low level fos expression. Studies on (hexachlorocyclohexane (HCH)) (lindane (delta HCH)) and diazepam (DZ) showed similar effects on the Na release test at similar concentrations suggesting a relationship with their known central nervous system (CNS) depressant activity.
Inhibition of butylbicyclophosphothionate [(355) TBPS] binding by convulsant polychlorocycloalkanes (PCCAs) correlates with their lethal dose (LD 50) values.
This neurotechnological proposal provides a multi-disciplinary approach with input from biochemists, pharmacologists, molecular biologists, immunologists and toxicologists to develop and validate in-vitro neuronal and non-neuronal cell systems for use in screening and testing compounds in order to evaluate (1) their potential for use as anticonvulsants; neuroprotective agents in excitotoxin-mediated neurodegenerative disease e.g. ischaemia, epilepsy; anti-gliosis agents and anti-cancer drugs; and (2) their deleterious effect as causative agents in the processes of cytotoxicity, terato-genicity and epilepogenicity and other convulsive states. It builds on the expertise generated by the BAP contractors and the ELWW on 'In-vitro screening in Neurotoxicology and pharmacology using neural primary cultures and cell lines'. The cell systems will include human and rodent brain cell lines (neuroblastoma and glioma) rodent primary cultures (neurons and astrocytes) and the multicellular brain slice system. End- points to be evaluated include receptor mediated cytotoxicity; anti-proliferative index; differentiation gene markers and inhibition of synaptic function including neurotransmitter release, receptor occupancy, receptor-effector coupling and downstream signalling events. Systems will be evaluated for reproducibility, in-vitro/in-vivo correlations and activity predictions based on computer-assisted molecular structural modelling.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Dati non disponibili

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN
Contributo UE
Nessun dato
Indirizzo
College Green
4 DUBLIN
Irlanda

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (4)

Il mio fascicolo 0 0